Literature DB >> 9474443

Cognitive functioning and GABAA/benzodiazepine receptor binding in schizophrenia: a 123I-iomazenil SPET study.

S Ball1, G F Busatto, A S David, S H Jones, D R Hemsley, L S Pilowsky, D C Costa, P J Ell, R W Kerwin.   

Abstract

BACKGROUND: The role of the inhibitory neurotransmitter gamma aminobutyric acid (GABA) in schizophrenia has previously been investigated using postmortem material. Recently, using single photon emission tomography (SPET) with the selective benzodiazepine antagonist 123I-Iomazenil as the radioligand, we have demonstrated an in vivo relationship between reduced GABAA/benzodiazepine receptor binding and the severity of positive symptomatology in schizophrenia. The present study aimed to build on this using the same in vivo scanning techniques, and relating findings to cognitive functioning.
METHODS: Ten nonpsychiatric control subjects and 15 schizophrenic patients, matched for age and handedness, were scanned. A battery of neuropsychologic tests was also administered.
RESULTS: Correlational analysis revealed a pattern of increased correlations between GABAA/benzodiazepine receptor binding and task performance, in the schizophrenic group compared to the control group.
CONCLUSIONS: Findings are preliminary but suggest a relationship between reduced GABAA/benzodiazepine receptor binding and poorer cognitive functioning, involving memory and visual attention processes, in the schizophrenic group but not in the control group. A role for GABA in the pathophysiology of schizophrenia is suggested. Limitations of the present study and suggestions for future research are discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9474443     DOI: 10.1016/s0006-3223(97)00300-4

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  8 in total

Review 1.  GABA abnormalities in schizophrenia: a methodological review of in vivo studies.

Authors:  Stephan F Taylor; Ivy F Tso
Journal:  Schizophr Res       Date:  2014-10-25       Impact factor: 4.939

2.  Decreased γ-aminobutyric acid levels in the parietal region of patients with Alzheimer's disease.

Authors:  Xue Bai; Richard A E Edden; Fei Gao; Guangbin Wang; Lebin Wu; Bin Zhao; Minzhong Wang; Queenie Chan; Weibo Chen; Peter B Barker
Journal:  J Magn Reson Imaging       Date:  2014-05-27       Impact factor: 4.813

3.  Phencyclidine/schizophrenia: one view toward the past, the other to the future.

Authors:  Edward F Domino; Elliot D Luby
Journal:  Schizophr Bull       Date:  2012-03-05       Impact factor: 9.306

4.  Probing GABA receptor function in schizophrenia with iomazenil.

Authors:  Kyungheup Ahn; Roberto Gil; John Seibyl; Richard Andrew Sewell; Deepak Cyril D'Souza
Journal:  Neuropsychopharmacology       Date:  2010-11-10       Impact factor: 7.853

5.  Reduced binding potential of GABA-A/benzodiazepine receptors in individuals at ultra-high risk for psychosis: an [18F]-fluoroflumazenil positron emission tomography study.

Authors:  Jee In Kang; Hae-Jeong Park; Se Joo Kim; Kyung Ran Kim; Su Young Lee; Eun Lee; Suk Kyoon An; Jun Soo Kwon; Jong Doo Lee
Journal:  Schizophr Bull       Date:  2013-04-15       Impact factor: 9.306

6.  Role of GABA Deficit in Sensitivity to the Psychotomimetic Effects of Amphetamine.

Authors:  Kyung-Heup Ahn; Andrew Sewell; Jacqueline Elander; Brian Pittman; Mohini Ranganathan; Handan Gunduz-Bruce; John Krystal; Deepak Cyril D'Souza
Journal:  Neuropsychopharmacology       Date:  2015-05-08       Impact factor: 7.853

Review 7.  Neuroimaging studies of GABA in schizophrenia: a systematic review with meta-analysis.

Authors:  A Egerton; G Modinos; D Ferrera; P McGuire
Journal:  Transl Psychiatry       Date:  2017-06-06       Impact factor: 6.222

8.  Increases in [3H]muscimol and [3H]flumazenil binding in the dorsolateral prefrontal cortex in schizophrenia are linked to α4 and γ2S mRNA levels respectively.

Authors:  Mathieu Verdurand; Stu G Fillman; Cynthia Shannon Weickert; Katerina Zavitsanou
Journal:  PLoS One       Date:  2013-01-08       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.